MedPath

Lisinopril

Generic Name
Lisinopril
Brand Names
Prinivil, Qbrelis, Zestoretic, Zestril
Drug Type
Small Molecule
Chemical Formula
C21H31N3O5
CAS Number
76547-98-3
Unique Ingredient Identifier
7Q3P4BS2FD

Overview

Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987.

Background

Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction. Lisinopril and captopril are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system. ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987.

Indication

Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure. A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.

Associated Conditions

  • Acute Myocardial Infarction (AMI)
  • Cardiovascular Events
  • Congestive Heart Failure (CHF)
  • Diabetic Nephropathy
  • Hypertension
  • Migraine

FDA Approved Products

Lisinopril and Hydrochlorothiazide
Manufacturer:A-S Medication Solutions
Route:ORAL
Strength:10 mg in 1 1
Approved: 2021/11/05
NDC:50090-6094
Lisinopril
Manufacturer:Northwind Pharmaceuticals
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/01/20
NDC:51655-232
Lisinopril and Hydrochlorothiazide
Manufacturer:QPharma Inc
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/12/08
NDC:42708-034
Lisinopril
Manufacturer:PD-Rx Pharmaceuticals, Inc.
Route:ORAL
Strength:20 mg in 1 1
Approved: 2024/01/24
NDC:72789-093
LISINOPRIL
Manufacturer:Accord Healthcare Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2024/03/13
NDC:16729-376

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath